Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
复制标题
DOI：
10.1097/00004424-199208000-00010
复制
发表时间：
1992-08
影响因子：
6.7
通讯作者：
O. Clément;A. Mühler;V. Vexler;Y. Berthezène;R. Brasch
中科院分区：
文献类型：
--
作者：
O. Clément;A. Mühler;V. Vexler;Y. Berthezène;R. Brasch
Gd-EOB-DTPA（Gd-EOB-DTPA）是一种新型的肝胆磁共振成像（MRI）造影剂，在正常大鼠中有70%通过肝脏和胆汁消除，30%通过肾脏消除。用组织弛豫法和MRI研究了这种新化合物的腹部增强模式和肝脏的摄取机制。方法12只正常大鼠、33只经胆汁排泄抑制剂处理的大鼠和6只胆总管结扎大鼠静脉注射Gd-EOB-DTPA。通过MR弛豫法测量分布和排泄。随时间推移测量肝脏、肾脏和肠的MR信号强度。结果在正常动物中，0.1mmol/kgGd-EOB-DTPA诱导的肝脏信号增强（200%）和持续时间（30 min时100%）均显著高于相同剂量的Gd-DTPA。无论是胆总管结扎引起的高胆红素血症，或溴磺酞（BSP）输液抑制肝摄取的Gd-EOB-DTPA，导致通过肾脏的优先消除。胆汁酸转运体抑制剂牛磺胆酸盐（TC）不能阻断肝摄取Gd-EOB-DTPA。Gd-EOB-DTPA在大鼠体内的血液半衰期为第一种成分2.4分钟，第二种成分8.2分钟。结论Gd-EOB-DTPA经肝脏进入胆汁的转运是由有机阴离子转运体驱动的。肝、肾强化之间的关系对间接评价肝排泄功能有一定的诊断价值。然而，即使存在严重的高胆红素血症，肝脏的持续增强也足以识别局灶性肿块病变。
OBJECTIVES Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) is a new hepatobiliary magnetic resonance imaging (MRI) contrast agent with a dual elimination: 70% via the liver and bile and 30% via the kidney in normal rats. The abdominal enhancement patterns of this new compound and the uptake mechanism by the liver were studied in rats using tissue relaxometry and MRI. METHODS Twelve normal rats, 33 rats treated with agents designed to inhibit biliary excretion of the agent, and 6 rats with surgically ligated common bile ducts received Gd-EOB-DTPA intravenously. Distribution and excretion were measured by MR relaxometry. MR signal intensity was measured over time for liver, kidney, and bowel. RESULTS In normal animals, 0.1 mmol/kg Gd-EOB-DTPA induced a significantly greater (200%) and more prolonged liver signal enhancement (100% at 30 minutes) than Gd-DTPA at the same dose. Either hyperbilirubinemia, induced by common bile duct ligation, or bromosulfophtalein (BSP) infusion inhibited liver uptake of Gd-EOB-DTPA, resulting in a preferential elimination via the kidney. Taurocholate (TC), an inhibitor of the bile acid transporter, was unable to block the liver uptake of Gd-EOB-DTPA. Blood half-lives of Gd-EOB-DTPA in rats were 2.4 minutes for the first component and 8.2 minutes for the second. CONCLUSIONS Data indicate that transport of Gd-EOB-DTPA through the liver into bile is driven by the organic anion transporter. The relation between enhancement of liver and kidney may be diagnostically useful to indirectly evaluate liver excretory function. Yet, persistent enhancement of liver, even in the presence of severe hyperbilirubinemia, should be sufficient to identify focal mass lesions.